Dishman Carbogen Amcis Ltd (DCAL) — shareholding pattern, promoter holding, financials and share price
About Dishman Carbogen Amcis Ltd (DCAL)
Dishman Carbogen Amcis Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as DCAL and on the BSE under scrip code 540701. Its ISIN is INE385W01011.
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries. [1]
Dishman Carbogen Amcis Limited is a global CDMO specializing in complex active pharmaceutical ingredients (APIs) and high active ingredients, serving biotech and pharmaceutical markets.
The company is expanding its integrated CDMO capabilities with ongoing expansions at facilities in Switzerland, France, and India to accommodate rising customer demands.
Listed peers in Pharmaceuticals: Morepen Laboratories Ltd, Panacea Biotec Ltd, Hikal Ltd, Solara Active Pharma Sciences Ltd, Kwality Pharmaceuticals Ltd, Sai Parenterals Ltd.
Valuation & Returns
10 Jul 2026At ₹195.7 a share on 10 Jul 2026, Dishman Carbogen Amcis Ltd (DCAL) was valued at a price-to-earnings ratio of 31.49x against an industry P/E of 36.41x and a price-to-book of 0.53x on a book value of ₹371.95 per share as of Mar 2025. Solomo computes return on equity of 1.67% and return on capital employed of 3.39% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 31.49x
- Industry P/E
- 36.41x
- P/B
- 0.53x
- EPS (TTM)
- ₹6.22
- Book value / share
- ₹371.95
- ROE
- 1.67%
- ROCE
- 3.39%
- ROA
- 0.97%
- Debt / equity
- 0.41x
- Dividend yield
- 0%
- EBITDA margin
- 21.07%
- 52-week range
- ₹129 – ₹321.15
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Dishman Carbogen Amcis Ltd (DCAL) reported revenue of ₹2,932 crore, net profit of ₹97 crore and earnings per share of ₹6.22. That compares with revenue of ₹2,712 crore and net profit of ₹3 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹851 crore and net profit ₹22 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2,141 | 2,413 | 2,616 | 2,712 | 2,932 |
| Net profit (₹ cr) | 18 | -30 | -153 | 3 | 97 |
| EPS (₹) | 1.15 | -1.9 | -9.79 | 0.21 | 6.22 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 57.23% | -7.19% | 9.25% | 3.66% |
| Profit growth | - | - | - | 102.11% |
| Stock price CAGR | - | -2% | 12% | -26% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 59.32% of Dishman Carbogen Amcis Ltd (DCAL) (unchanged from the previous quarter), foreign institutional investors (FII) hold 6.86% and domestic institutional investors (DII) hold 2.07%. Market capitalisation was ₹3,068 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2017.
Largest disclosed public shareholders in Jun 2026: Mukul Mahavir Agrawal 5.5%, Massachusetts Institute Of Technology 2.28%, Hbm Healthcare Investments (Cayman) Ltd 2.19%, Hsbc Mutual Fund - Hsbc Flexi Cap Fund 1.41%, HUF 1.07%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 59.32% | - | 6.86% | 2.07% | 40.68% |
| Mar 2026 | 59.32% | - | 7.45% | 1.63% | 40.68% |
| Dec 2025 | 59.32% | - | 7.66% | 1.27% | 40.68% |
| Sep 2025 | 59.32% | - | 8.07% | 1.37% | 40.68% |
| Jun 2025 | 59.32% | - | 9.93% | 1.27% | 40.68% |
| Mar 2025 | 59.32% | - | 9.49% | 1.26% | 40.68% |
| Dec 2024 | 59.32% | - | 8.75% | 1.42% | 40.68% |
| Sep 2024 | 59.32% | - | 8.17% | 1.23% | 40.68% |